Form 8-K - Current report:
SEC Accession No. 0001193125-20-194024
Filing Date
2020-07-16
Accepted
2020-07-16 16:38:59
Documents
9
Period of Report
2020-07-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d95772d8k.htm 8-K 26167
2 EX-1.1 d95772dex11.htm EX-1.1 274222
3 EX-4.1 d95772dex41.htm EX-4.1 59463
4 EX-5.1 d95772dex51.htm EX-5.1 7250
5 EX-99.1 d95772dex991.htm EX-99.1 10312
6 EX-99.2 d95772dex992.htm EX-99.2 10296
7 EX-99.3 d95772dex993.htm EX-99.3 10589
8 GRAPHIC g95772dsp16a.jpg GRAPHIC 12625
9 GRAPHIC g95772g0716233434680.jpg GRAPHIC 2694
  Complete submission text file 0001193125-20-194024.txt   421126
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 201031797
SIC: 2834 Pharmaceutical Preparations